Quick Answer
Tenaya Therapeutics, Inc. reported R&D Expense of $68.61 million for fiscal year 2025.
Tenaya Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $68.61M | -20.9% |
| 2024 | $86.74M | -11.5% |
| 2023 | $98.04M | +3.7% |
| 2022 | $94.54M | +73.8% |
| 2021 | $54.39M | +74.9% |
| 2020 | $31.10M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $15.36M | -24.5% | -11.6% |
| June 30, 2025 | $17.37M | -23.3% | -17.6% |
| March 31, 2025 | $21.08M | -15.9% | +3.6% |
| September 30, 2024 | $20.35M | -11.9% | -10.2% |
| June 30, 2024 | $22.65M | -14.5% | -9.6% |
| March 31, 2024 | $25.05M | -2.1% | +8.5% |
| September 30, 2023 | $23.09M | -2.8% | -12.8% |
| June 30, 2023 | $26.48M | +26.8% | +3.4% |
- Tenaya Therapeutics, Inc. showed a decrease of -20.9% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Tenaya Therapeutics, Inc.’s r&d expense has grown by 120.6% (from $31.10 million to $68.61 million).
- The most recent figure is from Tenaya Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: